These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system. Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715 [TBL] [Abstract][Full Text] [Related]
28. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy. Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372 [TBL] [Abstract][Full Text] [Related]
29. Interest of next-generation sequencing in BCG-treated high-risk bladder cancer. Jungels C; Martinez Chanza N; Albisinni S; Mercier M; d'Haene N; Rorive S; Roumeguère T Prog Urol; 2018 May; 28(6):344-350. PubMed ID: 29673906 [TBL] [Abstract][Full Text] [Related]
30. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables. Altieri VM; Castellucci R; Palumbo P; Verratti V; Sut M; Olivieri R; Manco R; Ricciardulli S; Nicolai M; Criniti P; Tenaglia RL Urol Int; 2012; 89(1):61-6. PubMed ID: 22722366 [TBL] [Abstract][Full Text] [Related]
31. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC). Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708 [TBL] [Abstract][Full Text] [Related]
32. Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer. von der Emde L; Goltz D; Latz S; Müller SC; Kristiansen G; Ellinger J; Syring I Am J Cancer Res; 2014; 4(6):952-62. PubMed ID: 25520883 [TBL] [Abstract][Full Text] [Related]
33. EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice? Busato Júnior WF; Almeida GL; Ribas CA; Ribas Filho JM; De Cobelli O Clin Genitourin Cancer; 2016 Apr; 14(2):176-82. PubMed ID: 26444918 [TBL] [Abstract][Full Text] [Related]
34. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer. Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. van Rhijn BW; Liu L; Vis AN; Bostrom PJ; Zuiverloon TC; Fleshner NE; van der Aa MN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Bapat B; van der Kwast TH; Zlotta AR BJU Int; 2012 Oct; 110(8):1169-76. PubMed ID: 22448597 [TBL] [Abstract][Full Text] [Related]
36. Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment. Blinova E; Roshchin D; Kogan E; Samishina E; Demura T; Deryabina O; Suslova I; Blinov D; Zhdanov P; Osmanov U; Nelipa M; Kaprin A Cells; 2019 May; 8(6):. PubMed ID: 31159302 [TBL] [Abstract][Full Text] [Related]
37. Deregulation of HOX B13 expression in urinary bladder cancer progression. Marra L; Cantile M; Scognamiglio G; Perdonà S; La Mantia E; Cerrone M; Gigantino V; Cillo C; Caraglia M; Pignata S; Facchini G; Botti G; Chieffi S; Chieffi P; Franco R Curr Med Chem; 2013 Feb; 20(6):833-9. PubMed ID: 23276138 [TBL] [Abstract][Full Text] [Related]